199 related articles for article (PubMed ID: 37782515)
41. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
Burton JM; O'Connor PW; Hohol M; Beyene J
Cochrane Database Syst Rev; 2012 Dec; 12():CD006921. PubMed ID: 23235634
[TBL] [Abstract][Full Text] [Related]
42. Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis.
Fahrbach K; Huelin R; Martin AL; Kim E; Dastani HB; Rao S; Malhotra M
BMC Neurol; 2013 Nov; 13():180. PubMed ID: 24245966
[TBL] [Abstract][Full Text] [Related]
43. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
44. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
Zhang J; Shi S; Zhang Y; Luo J; Xiao Y; Meng L; Yang X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD010968. PubMed ID: 29178444
[TBL] [Abstract][Full Text] [Related]
45. Olfactory threshold as a biomarker of long-term relapse activity in multiple sclerosis.
Berek K; Hegen H; Auer M; Barket R; Di Pauli F; Hocher J; Krajnc N; Zinganell A; Deisenhammer F; Berger T; Bsteh G
Mult Scler Relat Disord; 2024 May; 85():105545. PubMed ID: 38479044
[TBL] [Abstract][Full Text] [Related]
46. Effect of smoking on disease activity in multiple sclerosis patients treated with dimethyl fumarate or fingolimod.
Tanaka E; Watanabe M; Fukumoto S; Masaki K; Yamasaki R; Matsushita T; Isobe N
Mult Scler Relat Disord; 2023 Feb; 70():104513. PubMed ID: 36689892
[TBL] [Abstract][Full Text] [Related]
47. Odour discrimination and identification as a biomarker of long-term disability worsening in multiple sclerosis.
Berek K; Hegen H; Auer M; Barket R; Di Pauli F; Hocher J; Krajnc N; Zinganell A; Deisenhammer F; Berger T; Bsteh G
Mult Scler; 2024 Jan; 30(1):55-62. PubMed ID: 37850472
[TBL] [Abstract][Full Text] [Related]
48. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
49. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
[TBL] [Abstract][Full Text] [Related]
50. Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis.
Bsteh G; Hegen H; Altmann P; Auer M; Berek K; Pauli FD; Wurth S; Zinganell A; Rommer P; Deisenhammer F; Leutmezer F; Berger T
Mult Scler J Exp Transl Clin; 2020; 6(4):2055217320966344. PubMed ID: 33194221
[TBL] [Abstract][Full Text] [Related]
51. Use of rituximab in adults with relapsing-remitting multiple sclerosis: a systematic literature review.
Siddiqui MK; Singh B; Attri S; Veraart C; Harty G; Wong SL
Curr Med Res Opin; 2020 May; 36(5):809-826. PubMed ID: 32129684
[No Abstract] [Full Text] [Related]
52. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
[TBL] [Abstract][Full Text] [Related]
53. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
54. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
Roskell NS; Zimovetz EA; Rycroft CE; Eckert BJ; Tyas DA
Curr Med Res Opin; 2012 May; 28(5):767-80. PubMed ID: 22462530
[TBL] [Abstract][Full Text] [Related]
55. Fingolimod for relapsing-remitting multiple sclerosis.
La Mantia L; Tramacere I; Firwana B; Pacchetti I; Palumbo R; Filippini G
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009371. PubMed ID: 27091121
[TBL] [Abstract][Full Text] [Related]
56. Natalizumab for relapsing remitting multiple sclerosis.
Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
[TBL] [Abstract][Full Text] [Related]
57. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
[TBL] [Abstract][Full Text] [Related]
58. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.
Scalfari A; Neuhaus A; Degenhardt A; Rice GP; Muraro PA; Daumer M; Ebers GC
Brain; 2010 Jul; 133(Pt 7):1914-29. PubMed ID: 20534650
[TBL] [Abstract][Full Text] [Related]
59. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
[TBL] [Abstract][Full Text] [Related]
60. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]